帕罗西汀联合唑吡坦治疗抑郁症失眠的临床疗效研究

摘要

Objective To study the clinical efficacy of paroxetine combined with zolpidem in the treatment of depression and insomnia.Methods According to double-blind randomized grouping principle,74 patients with depression and insomnia treated at our hospital from March,2017 to February,2018 were divided into a control group and an observation group,37 cases for each group.The control group were treated with paroxetine,and the observation group with paroxetine and zolpidem.The treatment effects,the Hamilton Depression Scale(HAMD)scores,the Pittsburgh Sleep Quality Index Rating Scale(PSQI) scores,and the incidences of adverse reactions were compared between these two groups.Results The total clinical effective rate was higher in the observation group than in the control group [94.59％ (35/37) vs.75.68％ (28/37),P ＜ 0.05].After the treatment,the scores of HAMD and PSQI were (12.03±4.13) and (6.20±2.26) in the observation group,which were lower than those in the control group (both P ＜ 0.05).The incidence of adverse reactions was lower in the observation group than in the control group [5.41％ (2/37) vs.27.03％ (10/37)].Conclusion Paroxetine combined with zolpidem for patients with depression and insomnia is helpful for the improvement of depression and insomnia.%目的 研究帕罗西汀联合唑吡坦治疗抑郁症失眠的临床疗效.方法 选取2017年3月至2018年2月期间本院接收的抑郁症失眠患者74例,根据双盲随机分组原则分为两组,各37例.对照组采取帕罗西汀治疗,观察组实施帕罗西汀联合唑吡坦治疗.将两组抑郁症失眠患者的治疗效果、汉密尔顿抑郁量表(HAMD)评分、匹兹堡睡眠质量指数评定量表(PSQI)评分、不良反应发生情况进行比对.结果 观察组临床总有效率94.59％(35/37),高于对照组75.68％(28/37),差异有统计学意义(P＜0.05);治疗前,两组患者HAMD评分、PSQI评分比较,差异均无统计学意义(均P＞0.05);治疗后,观察组HAMD评分、PSQI评分分别为(12.03±4.13)分、(6.20±2.26)分,均低于对照组,差异均有统计学意义(均P＜ 0.05);观察组不良反应发生率5.41％(2/37),低于对照组27.03％(10/37),差异有统计学意义(P＜0.05).结论 抑郁症失眠患者采用帕罗西汀联合唑吡坦治疗有助于其抑郁程度、失眠状况的改善,安全有效.